624 related articles for article (PubMed ID: 35320468)
41. New investigational combinations for higher-risk MDS.
Koenig KL; Borate U
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):368-374. PubMed ID: 36485141
[TBL] [Abstract][Full Text] [Related]
42. Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
Bewersdorf JP; Zeidan AM
Leuk Lymphoma; 2020 Oct; 61(10):2295-2312. PubMed ID: 32421403
[TBL] [Abstract][Full Text] [Related]
43. Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress.
Venugopal S; Shallis RM; Zeidan AM
Expert Rev Anticancer Ther; 2023; 23(9):903-911. PubMed ID: 37470508
[TBL] [Abstract][Full Text] [Related]
44. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS).
Almeida A; Fenaux P; List AF; Raza A; Platzbecker U; Santini V
Leuk Res; 2017 Jan; 52():50-57. PubMed ID: 27883945
[TBL] [Abstract][Full Text] [Related]
45. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
Greenberg PL; Cosler LE; Ferro SA; Lyman GH
J Natl Compr Canc Netw; 2008 Oct; 6(9):942-53. PubMed ID: 18926103
[TBL] [Abstract][Full Text] [Related]
46. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
47. Therapy for lower-risk MDS.
Carraway HE; Saygin C
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):426-433. PubMed ID: 33275714
[TBL] [Abstract][Full Text] [Related]
48. Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
Volpe VO; Komrokji RS
Ther Adv Hematol; 2021; 12():2040620720986641. PubMed ID: 33505645
[TBL] [Abstract][Full Text] [Related]
49. Can Lower-Risk MDS Achieve High Reward with Hypomethylating Agent Therapy?
Bejar R
NEJM Evid; 2022 Oct; 1(10):EVIDe2200165. PubMed ID: 38319862
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.
Pophali P; Desai SR; Shastri A
Curr Hematol Malig Rep; 2023 Jun; 18(3):56-67. PubMed ID: 37052811
[TBL] [Abstract][Full Text] [Related]
51. BMT for Myelodysplastic Syndrome: When and Where and How.
Jain AG; Elmariah H
Front Oncol; 2021; 11():771614. PubMed ID: 35070975
[TBL] [Abstract][Full Text] [Related]
52. Therapeutic approaches for the management of higher risk myelodysplastic syndromes.
Wang C; Sallman DA
Leuk Lymphoma; 2023 Mar; 64(3):511-524. PubMed ID: 36433645
[TBL] [Abstract][Full Text] [Related]
53. [Current management of myelodysplastic syndromes].
Vey N; Charbonnier A
Rev Prat; 2010 Dec; 60(10):1416-9. PubMed ID: 21425543
[TBL] [Abstract][Full Text] [Related]
54. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
55. [Management of lower-risk myelodysplastic syndromes].
Ichikawa M
Rinsho Ketsueki; 2020; 61(9):1212-1217. PubMed ID: 33162518
[TBL] [Abstract][Full Text] [Related]
56. The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances.
Randall MP; DeZern AE
Cancer J; 2023 May-Jun 01; 29(3):152-159. PubMed ID: 37195771
[TBL] [Abstract][Full Text] [Related]
57. Treatment of MDS.
Platzbecker U
Blood; 2019 Mar; 133(10):1096-1107. PubMed ID: 30670446
[TBL] [Abstract][Full Text] [Related]
58. [Myelodysplastic syndromes].
Thol F; Heuser M; Ganser A
Internist (Berl); 2015 Apr; 56(4):364-73. PubMed ID: 25700647
[TBL] [Abstract][Full Text] [Related]
59. How we treat lower-risk myelodysplastic syndromes.
Fenaux P; Adès L
Blood; 2013 May; 121(21):4280-6. PubMed ID: 23575446
[TBL] [Abstract][Full Text] [Related]
60. [Recent findings in myelodysplastic syndrome].
Petzer V; Wolf D
Dtsch Med Wochenschr; 2023 Nov; 148(22):1431-1436. PubMed ID: 37918427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
